Raising a Series A in healthtech.
At Series A, healthtech investors want to see that buyers pay, renew and expand. Here is the bar and who usually leads.
Healthtech
Healthtech investors look past the demo to three questions: who pays, what evidence proves it works, and whether you can handle patient data safely. Long sales cycles shape every round.
What Series A investors expect in healthtech
Pilots are no longer enough. Expect diligence on each of these.
Contracts that renew
- Several paying customers of the same buyer type
- Pilots that turned into multi-year contracts
- Expansion inside existing health systems or plans
Validation buyers trust
- Outcome or savings data from real deployments
- A published or peer-reviewed study, or one underway
- A clear answer to whether you need FDA review
A repeatable sale
- A known sales cycle and who is in the buying committee
- Integration with records systems that does not stall deals
- A security and privacy posture that passes buyer review
How the round comes together
Series A healthtech rounds are usually led by a venture fund with dedicated health partners.
- 1 · A venture fund leads
- 2 · Existing investors keep their share
- 3 · Strategics join
Multi-stage VCs
Often leads
Funds with health care teams lead most healthtech Series A rounds.
Pre-seed & seed funds
Often follows
Seed investors usually take their pro-rata.
Corporate VCs
Sometimes
Insurers, health systems and pharma join when a partnership is live.
Family offices
Sometimes
Families with health care history co-invest beside the lead.
A priced round with a board
Series A is almost always priced equity. Expect a lead to set the valuation, take a board seat and ask for standard protections. Strategic investors may ask for information or first-look rights; check what they cost you.
The slides investors read first
Customers
Paying buyers, contract length and renewals.
Outcomes
Clinical or cost results from deployments.
Go-to-market
Sales cycle, buying committee, win rate.
Compliance
HIPAA, security reviews and any FDA path.
The plan
What the round buys and the milestones for B.
Questions founders ask
When is a healthtech company ready for Series A?
When pilots have turned into paid, renewing contracts and you can explain why the next buyer will sign faster. A few quarters of revenue data beat one large logo.
Do I need a peer-reviewed study for Series A?
Not always. Many buyers accept strong real-world outcome data. If your buyers or a regulator expect a formal study, investors want to see one planned and funded.
Sources
Sources: HHS guidance on HIPAA; FDA guidance on digital health software; CMS reimbursement resources; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.